tbuckley/cabot-search huggingface dataset:
P761: UMBILICAL CORD BLOOD ORIGIN CELLS RECONSTRUCT THE HEMATOPOIESIS OF APLASTIC ANEMIA ANIMAL MODEL
Authors: Zesong Chen, Jiang Ji, Chen Yang, Bing Han, Miao Chen
Journal: HemaSphere (2023)

Topic: 11. Bone marrow failure syndromes incl. PNH - Biology & Translational Research Background:Aims: To explore the efficacy and the mechanism of umbilical cord origin cells in combined with cyclosporine A (CsA) in the treatment of aplastic anemia (AA) mouse model. Methods: Immune-mediated AA model mice were treated with CsA+ mesenchymal stem cells (UC-MSC); CsA+ umbilical cord blood regulatory T cells (UCB-Treg); UC-MSC; UCB-Treg; CsA alone or nothing, separately, with 9 mice in each group. CsA was given from the first day of modeling (d0), and cell infusion was given at the same day. Peripheral blood routine test once a week, bone marrow colony culture, bone marrow cell flow cytometry, peripheral blood T cell subsets and serum inflammatory cytokines test at d14 were performed. Transcriptome sequencing was performed for cells from CsA+UC-MSC, CsA+UCB-Treg and CsA group to find the possible related genes. Gene function cluster and signal pathway enrichment analysis were carried out next. Results: Mice transfused with blank control died from pancytopenia within 21 days whereas other mice survived over 28 days. At day 14, WBC count was higher in CsA+UC-MSC and CsA+UCB-Treg groups compared with the other groups(p<0.05). Accordingly, higher BFU and CFU-GM colony count (p<0.01) was found in CsA+UC-MSC and CsA+UCB-Treg groups, and even higher BFU colony count in CsA+UC-MSC group (p<0.01). The highest bone marrow CD34+ cell proportion was in CsA+UC-MSC (9.68±1.35%) and CsA+UCB-Treg group (8.17±0.53%) (p<0.01) as well. TNF-α and IL-2 level in CsA+UC-MSC group (p<0.05) and TNF-α, IL-2 and INF-γ level in CsA+UC-Treg group (p<0.01) were lower compared with CsA group. CsA+UC-MSC had significantly down-regulated histone methylation pathway (p<0.05) whereas CsA+UCB-Treg had significantly up-regulated energy metabolism processes (p<0.05) compared with CsA. Meanwhile, CsA+UC-MSC had up-regulated superoxide dismutase activity compared with CsA+UCB-Treg group. Summary/Conclusion: Adding UC-MSC or UCB-Treg to CsA significantly increased the hematopoiesis reconstruction of AA mice, and UC-MSC was more efficient than UCB-Treg. Adding these cells can further improve the immune abnormalities. CsA+UC-MSC reduced histone methylation pathway and the CsA-UCB-Treg increased energy metabolism processes compared with CsA alone. Keywords: Umbilical cord blood, Mesenchymal stem cell, Regulatory T cell, Aplastic anemia
P902: ISATUXIMAB, WEEKLY CARFILZOMIB AND DEXAMETHASONE AS SALVAGE THERAPY FOR RRMM; INTERIM RESULTS FROM A PHASE 2 TRIAL.
Authors: David H. Vesole, Jesus Berdeja, Jeffrey Matous, Suzanne Trudel, Henning Schade, Pamela Munster, Savannah Berkeley, Benjamin Sun, Tom Martin
Journal: HemaSphere (2023)

Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: There are many considerations when selecting treatment for relapsed MM including treatment-related (safety and response rates) and patient-related (tolerability and convenience) factors. Triplet-based regimens that combine active classes of drugs (PI, IMiD and CD38 antibodies) are preferred. Updated results from the IKEMA study reported a PFS of 35.7 months in patients receiving isatuximab, twice weekly high-dose carfilzomib(56mg/m2) and dex(Isa-Kd). Aims: The aim of this study was to assess the safety and efficacy of Isa-Kd utilizing once weekly high-dose K (70 mg/m2) in patients with relapsed multiple myeloma. Methods: Eligible pts had RRMM, received at least 1 but no more than 3 prior lines of therapy, had no prior exposure to CD38 antibodies and could have received K but could not be K refractory. Patients were required to have adequate blood counts and organ function. Pts received standard dose Isa 10 mg/kg IV Qwk x 4 doses then ISA 10 mg/kg IV every other week, K 20 mg/m2 on C1D1 then K 70 mg/m2 C1D8 and 15 and on D1, 8, 15 in subsequent 28-day cycles, and dex 40 mg Qwk. This study was developed in cooperation with the Multiple Myeloma Research Consortium and 5 sites are actively enrolling subjects. Results: As of January 31, 2023; 33 patients have been enrolled, median follow-up is 9 mo (range, 2.0–27). Median age is 64 y (range, 35–83; 12pts 70+); 20M, 13F; 34% of pts had high cytogenetic risk and an additional 22% had isolated 1q21 gain/amp. Pts had a median of 1 prior LOT (range, 1–3): 100% IMiD and PI exposed; 43% Len refractory. The most common hematologic toxicity was thrombocytopenia (21%; 15% Gr2/3). The most common non-hematologic adverse events (incidence >20%) were hypertension (HTN) (48%: 18% Gr3), infection (45%, 3% Gr3), infusion reactions (39%; all Gr 1/2), fatigue (33%), dyspnea (27%), insomnia (21%) and ALT elevation (21%). Cardiovascular AE’s were seen in 3 patients (Gr3 MI, Gr2 DVT, Gr2 pulmonary edema). The ORR was 87.5% (sCR/CR 2, VGPR 18, PR 8; 62.5% ≥VGPR). Median time to first response was 28 days (range 28-NR); median DOR was not reached and treatment is on-going in 24/33. No patients discontinued therapy due to an adverse event. Summary/Conclusion: The combination of Isa + weekly Kd appears safe with manageable side effects. Rapid responses have been seen with an ORR of 87.55% (62.5% achieving ≥VGPR) and responses deepening over time. No unexpected safety signals have been noted and these early results support the use of Isa-with weekly Kd in patients with relapsed MM. Keywords: Multiple myeloma, Myeloma
P933: INDIRECT TREATMENT COMPARISON OF ELRANATAMAB WITH BELMAF, SEL-DEX, AND REAL-WORLD PHYSICIAN’S CHOICE OF TREATMENT IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA.
Authors: Isha Mol, Yannan Hu, Joseph Cappelleri, Haitao Chu, Didem Aydin, Patrick Hlavacek
Journal: HemaSphere (2023)

Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: Elranatamab, a bispecific antibody targeting B-cell maturation antigen on multiple myeloma (MM) cells and CD3 on T cells, is being evaluated as a monotherapy in the MagnetisMM-3 trial (MM3; NCT04649359) in patients with triple-class exposed (TCE) relapsed/refractory MM. While there is no standard of care for TCE MM, belantamab mafodotin (belamaf) and selinexor plus dexamethasone (sel-dex) are treatment options. LocoMMotion is a prospective, non-interventional study investigating real-world physician’s choice of treatment (PCT) in patients with TCE MM. Aims: In the absence of head-to-head trials, unanchored matching-adjusted indirect comparisons (MAIC) were conducted to compare the relative efficacy across comparators. Methods: Individual patient-level data were obtained for elranatamab from MM-3 (data cut Oct 2022). Aggregated data for belamaf, sel-dex, and PCT were obtained from DREAMM-2 (NCT03525678), STORM (NCT02336815), and LocoMMotion (NCT04035226). Unanchored MAICs were conducted to compare the relative treatment effect on objective response rate (ORR) accounting for potential different distributions of prognostic variables (PVs) and effect modifiers (EMs). In the base case, PVs identified via logistic regressions based on MM-3 data were adjusted. In sensitivity analyses, PVs/EMs identified from the literature were added. Relative treatment effects were measured by rate differences and odds ratios. Results: After MAIC adjustments, the selected PVs/EMs were balanced in each comparison. Table 1 presents the results from the naïve comparison with no MAIC adjustment plus the MAIC base case. The ORR of elranatamab was statistically higher than belamaf, sel-dex, and PCT in LocoMMotion. Results were consistent across all sensitivity analyses. Table 1 Unanchored MAIC results comparing Elranatamab to other treatments - MagnetisMM-3 Cohort A ORR Comparator ORR % Rate difference 1 (95% CI) Odds ratio (95% CI) p-value 2 Belantamab mafodotin Naïve comparison 61% 32% 29.0 (16.4, 41.7) 3.3 (1.9, 5.8) 0.000 MAIC base case 50% 32% 17.7 (4.1, 31.3) 2.1 (1.2, 3.8) 0.019 Naïve comparison 61% 26% 34.8 (23.1, 46.4) 4.4 (2.6, 7.6) 0.000 MAIC base case 57% 26% 30.8 (17.9, 43.6) 3.73 (2.1, 6.7) 0.000 PCT - LocoMMotion Naïve comparison 61% 30% 31.1 (20.8, 41.5) 3.7 (2.3, 5.8) 0.000 MAIC base case 57% 30% 27.6 (16.1, 39.1) 3.2 (1.9, 5.2) 0.000 ORR: objective response rate; CI: confidence interval.1The absolute difference between the ORR in each comparison.2p-values are from the two-sided Fisher’s exact test. Summary/Conclusion: Elranatamab had a significantly higher ORR than belamaf, sel-dex, and real-world PCT in LocoMMotion for patients with TCE MM, demonstrating its clear clinical benefit for this population. Keywords: Myeloma, Clinical trial, Bispecific, Multiple myeloma
P931: ISATUXIMAB IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH ULTRA-HIGH-RISK CYTOGENETICS: ICARIA-MM AND IKEMA SUBGROUP ANALYSIS
Authors: Philippe Moreau, Aurore Perrot, Meletios A. Dimopoulos, Thomas Martin, Thierry Facon, Marcelo Eduardo Capra, Meral Beksac, Nicole Armstrong, Franck Dubin, Sandrine Macé, Marie-Laure Risse, Christina Tekle, Zandra Klippel, Paul Richardson
Journal: HemaSphere (2023)

Topic: 14. Myeloma and other monoclonal gammopathies - Clinical Background: Patients (pts) with ultra-high-risk (UHR) multiple myeloma (MM) have even poorer prognosis than pts with no or 1 chromosomal abnormality (CA). Isatuximab (Isa) is an approved anti-CD38 monoclonal antibody that was evaluated in relapsed/refractory MM in ICARIA-MM and IKEMA. Aims: These analyses of ICARIA-MM and IKEMA data investigated Isa-Pd and Isa-Kd in pts with UHR and extended high-risk (EHR) MM. Methods: The analysis excluded pts with at least one missing CA information. Standard risk (SR) was the absence of the following CA – del(17p), t(4;14), t(14;16) and 1q21+; EHR the presence of only one of these CA, and UHR the presence of ≥2 CA. Results: In ICARIA-MM, there were 101 Isa-Pd (SR cytogenetics: 29; EHR CA: 61; UHR CA: 11) and 93 Pd (SR: 35; EHR CA: 38; UHR CA: 20) pts. In IKEMA, 154 Isa-Kd (SR: 65; EHR CA: 64; UHR CA: 25) and 103 Kd (SR: 43; EHR CA: 41; UHR CA: 19) pts were included. In both trials, all UHR pts had 1q21+, and t(4;14) was the second most frequent CA, followed by del(17p) and t(14;16). In ICARIA-MM, Isa-Pd led to a progression-free survival (PFS) benefit regardless of risk category (SR HR 0.478 [95% CI 0.263−0.866]; EHR HR 0.645 [95% CI 0.414−1.006]; UHR HR 0.437 [95% CI 0.188−1.018]). Hazard ratios for overall survival (OS) were 1.032 (95% CI 0.542−1.972), 0.842 (95% CI 0.533−1.330) and 0.796 (95% CI 0.357−1.776) for SR, EHR, and UHR pts, respectively. PFS benefits with Isa-Kd were also shown in IKEMA (SR HR 0.496 [95% CI 0.294−0.839]; EHR HR 0.531 [95% CI 0.310−0.908]; UHR HR 0.689 [95% CI 0.343−1.385]). OS data is immature. A summary of response rates for both trials is in the Table. Minimal residual disease negativity (MRD−) rate was 44.6% and 18.6% with Isa-Kd and Kd respectively in SR pts, 32.8% and 14.6% with EHR, and 28.0% and 21.1% with UHR. MRD− and complete response or higher rates were 33.8% and 11.6% with Isa-Kd and Kd in SR pts, 28.1% and 12.2% in EHR and 20.0% and 21.1% in UHR pts respectively. Summary/Conclusion: The benefit of Isa in all subgroups was consistent with the primary results of each study. A benefit in EHR pts with Isa-containing regimens vs control arms was observed, including pts with UHR, who would benefit from further improvement in outcomes.Keywords: Chromosomal abnormality, CD38, Monoclonal antibody, Multiple myeloma
P770: IDENTIFYING GENES ASSOCIATED WITH PROLIFERATION AND THROMBOSIS IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Authors: Yali Du, David Wang, Qinglin Hu, Jinzhi Lai, Chen Yang, Miao Chen, Huiwen He, Shuqing Wang, Huijuan Zhang, Peng Chen, Bing Han
Journal: HemaSphere (2023)

Topic: 11. Bone marrow failure syndromes incl. PNH - Biology & Translational Research Background: PIGA mutation could not fully explain the proliferative advantage of abnormal clone and thrombosis tendency in paroxysmal nocturnal hemoglobinuria (PNH), additional genes which may play a role worth further investigation. Thrombotic high-risk genes from different studies were not consistent, suggesting the complexities of gene-clinic relations which needs further investigations. Aims: We tried to find the possible genes related to the proliferations, immune regulations and thrombotic regulations for PNH CD59+ and CD59- cells, separately, and validated them in a larger PNH cohort. Methods: CD59+ and CD59- of peripheral blood leukocytes from 6 patients with PNH were sorted and sequenced by whole exon sequences (WES) and whole transcriptome, respectively. Six age- and sex-matched healthy volunteers were selected as controls. Genes related to proliferation, apoptosis, immunity and thrombosis were selected by Gene Ontology (GO) analysis. The selected genes were then identified in 40 patients’ WES results and finally verified by Sanger method in another 40 PNH patients to confirm the object genes. CD59+ and CD59- leukocytes from 7 patients were sorted and the RNA and protein expression of these object genes was further verified by Q-PCR, flow cytometry and western blot, separately. Then the final selected genes were correlated to the clinical features. Results: Up-regulated T-cell activation related genes and down-regulated platelet degranulation, coagulation, hemostasis, leukocyte proliferation, platelet activation related genes were found in both CD59+ and CD59- cells, with further down-regulated leukocyte proliferation, platelet activation, coagulation regulation related genes in CD59+ cells compared with CD59- cells (P<0.05). For the final selected candidate genes, patients with PNH clones between 11 and 20% had higher NRP1 and FLT1 mutations (P=0.01). Those with PNH clones between 11 and 85% had higher SELP, vWF and EpHB2 mutations (P=0.03). BMF/PNH patients had higher SWAP70, SLC15A4 or ABCA13 mutations than classic PNH (P=0.02). Patients with thrombosis had higher EpHB2 and lower SELP mutations (P<0.05). Summary/Conclusion: Patients with PNH had up-regulated T cell activation related genes and down-regulated proliferation and coagulation related genes, and CD59+ cells had further down-regulated proliferation and thrombosis regulation genes. Additional genes may involve in the proliferation and coagulopathy of PNH. Keywords: Paroxysmal nocturnal hemoglobinuria (PNH)
Mitochondria-specific near-infrared photoactivation of peroxynitrite upconversion luminescent nanogenerator for precision cancer gas therapy
Authors: Hui Yu, Aliya Tiemuer, Xufeng Yao, Mingyuan Zuo, Hai-Yan Wang, Yi Liu, Xiaoyuan Chen
Journal: Acta Pharmaceutica Sinica B (2023)

Gas therapy is emerging as a highly promising therapeutic strategy for cancer treatment. However, there are limitations, including the lack of targeted subcellular organelle accuracy and spatiotemporal release precision, associated with gas therapy. In this study, we developed a series of photoactivatable nitric oxide (NO) donors NRh-R-NO (R= Me, Et, Bn, iPr, and Ph) based on an N-nitrosated upconversion luminescent rhodamine scaffold. Under the irradiation of 808 nm light, only NRh-Ph-NO could effectively release NO and NRh-Ph with a significant turn-on frequency upconversion luminescence (FUCL) signal at 740 nm, ascribed to lower N‒N bond dissociation energy. We also investigated the involved multistage near-infrared-controlled cascade release of gas therapy, including the NO released from NRh-Ph-NO along with one NRh-Ph molecule generation, the superoxide anion O2•- produced by the photodynamic therapy (PDT) effect of NRh-Ph, and highly toxic peroxynitrite anion (ONOO‒) generated from the co-existence of NO and O2•-. After mild nano-modification, the nanogenerator (NRh-Ph-NO NPs) empowered with superior biocompatibility could target mitochondria. Under an 808 nm laser irradiation, NRh-Ph-NO NPs could induce NO/ROS to generate RNS, causing a decrease in the mitochondrial membrane potential and initiating apoptosis by caspase-3 activation, which further induced tumor immunogenic cell death (ICD). In vivo therapeutic results of NRh-Ph-NO NPs showed augmented RNS-potentiated gas therapy, demonstrating excellent biocompatibility and effective tumor inhibition guided by real-time FUCL imaging. Collectively, this versatile strategy defines the targeted RNS-mediated cancer therapy.
AMPK activation coupling SENP1-Sirt3 axis protects against acute kidney injury
Authors: Minyan Zhu, Jianli He, Yao Xu, Yong Zuo, Wenyan Zhou, Zhiying Yue, Xinghua Shao, Jinke Cheng, Tianshi Wang, Shan Mou
Journal: Molecular Therapy (2023)

Acute kidney injury (AKI) is a critical clinical condition that causes kidney fibrosis, and it currently lacks specific treatment options. In this research, we investigate the role of the SENP1-Sirt3 signaling pathway and its correlation with mitochondrial dysfunction in proximal tubular epithelial cells (PTECs) using folic acid (FA) and ischemia-reperfusion-induced (IRI) AKI models. Our findings reveal that Sirt3 SUMOylation site mutation (Sirt3 KR) or pharmacological stimulation (metformin) protected mice against AKI and subsequent kidney inflammation and fibrosis by decreasing the acetylation level of mitochondrial SOD2, reducing mitochondrial reactive oxygen species (mtROS), and subsequently restoring mitochondrial ATP level, reversing mitochondrial morphology and alleviating cell apoptosis. In addition, AKI in mice was similarly alleviated by reducing mtROS levels using N-acetyl-L-cysteine (NAC) or MitoQ. Metabolomics analysis further demonstrated an increase in antioxidants and metabolic shifts in Sirt3 KR mice during AKI, compared with Sirt3 wild-type (WT) mice. Activation of the AMPK pathway using metformin promoted the SENP1-Sirt3 axis and protected PTECs from apoptosis. Hence, the augmented deSUMOylation of Sirt3 in mitochondria, activated through the metabolism-related AMPK pathway, protects against AKI and subsequently mitigated renal inflammation and fibrosis through Sirt3-SOD2-mtROS, which represents a potential therapeutic target for AKI.
Steatotic liver disease as a new nomenclature for NAFLD from the perspectives of the MENA region: One size fits all this time
Authors: Mohamed El-Kassas, Khalid Alswat, Mina Tharwat, Asma Labidi, Mohammed A. Medhat, Faisal M. Sanai, Mustapha Benazzouz, Ali Tumi, Yusuf Yilmaz, Abdel-Naser Elzouki
Journal: Journal of Hepatology (2023)
Bile duct-associated macrophages enter the spotlight in inflammatory cholestatic liver disease
Authors: Moritz Peiseler, Frank Tacke
Journal: Hepatology (2023)

1Department of Hepatology & Gastroenterology, Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany 2BIH, Berlin Institute of Health, Berlin, Germany Correspondence Moritz Peiseler, Charité Universitätsmedizin Berlin, Hepatology & Gastroenterology. Email: [email protected] Correspondence Frank Tacke, Charité Universitätsmedizin Berlin, Hepatology & Gastroenterology. Email: [email protected]
Emerging and potential use of CRISPR in human liver disease
Authors: Salah Adlat, Alexandra M. Vázquez Salgado, Markcus Lee, Dingzi Yin, Kirk J. Wangensteen
Journal: Hepatology (2023)

CRISPR is a gene editing tool adapted from naturally occurring defense systems from bacteria. It is a technology that is revolutionizing the interrogation of gene functions in driving liver disease, especially through genetic screens and by facilitating animal knockout and knockin models. It is being used in models of liver disease to identify which genes are critical for liver pathology, especially in genetic liver disease, hepatitis, and in cancer initiation and progression. It holds tremendous promise in treating human diseases directly by editing DNA. It could disable gene function in the case of expression of a maladaptive protein, such as blocking transthyretin as a therapy for amyloidosis, or to correct gene defects, such as restoring the normal functions of liver enzymes fumarylacetoacetate hydrolase or alpha-1 antitrypsin. It is also being studied for treatment of hepatitis B infection. CRISPR is an exciting, evolving technology that is facilitating gene characterization and discovery in liver disease and holds the potential to treat liver diseases safely and permanently.
Transdermal Sustained Release Properties and Anti‐Photoaging Efficacy of Liposome‐Thermosensitive Hydrogel System
Authors: Sijie Wu, Gaodan Liu, Ping Shao, Xingyu Lin, Jiahao Yu, Hanchi Chen, Huiliang Li, Simin Feng
Journal: Advanced Healthcare Materials (2023)

Abstract Drug delivery systems have become a research priority in the biomedical field. The incorporation of liposomes to hydrogels further forms more robust multifunctional systems for more effective and sustained topical drug delivery. In this study, carboxymethyl‐modified chitosan/hyaluronic acid (CMC/HA, CMH) thermosensitive hydrogel is developed for sustained transdermal delivery of liposomes. Hydrogels are crosslinked by hydrogen bonding, hydrophobic interaction and electrostatic interaction. The gel properties can be regulated by substitution degree (DS), and when DS = 18.20 ± 0.67% (CMH2), the gel temperature is 37.8 °C, allowing rapid gelation at body temperature (315 s). Moreover, CMH2 hydrogel has suitable spreadability (17.7–57.2 cm 2 ), viscosity (2133.4 mPa s) and porous structure, which facilitated its adhesion and application on the skin and liposomes delivery. The hydrogel can retard the liposomes release, and the release rate of ascorbyl glucoside (AA2G) is 33.92–49.35% in 24 h. Hydrogel avoids the rapid clearance of liposomes from the skin and improved the skin retention, achieving the long‐term release of bioactive components. Liposome‐hydrogel system more efficiently promotes the anti‐photoaging effect of AA2G on skin, reducing epidermal thickness, melanin deposition and lipid oxidative damage and increasing collagen density. Therefore, liposome‐hydrogel systems are proposed as multifunctional delivery systems for sustained transdermal delivery.
Correction: A loop-assisted inversion technique for easy removal of a gastric stromal tumor in the fundus
Authors: Zhang Tao, Long Chen, Jie Liu, Yi Ming Peng, Feng Ying Lin, Liang Sun, Jian Chen
Journal: Endoscopy (2023)

Correction to: A loop-assisted inversion technique for easy removal of a gastric stromal tumor in the fundusEndoscopy 2023; 55(S 01): E902-E903DOI: 10.1055/a-2119-0999
Correction: Efficacy and cost-effectiveness of a novel dual grasping forceps-assisted over-the-scope clip inverted closure after gastric endoscopic full-thickness resection
Authors: Noriko Nishiyama, Shintaro Fujihara, Naoya Tada, Kaho Nakatani, Asahiro Morishita, Takayoshi Kishino, Hideki Kobara
Journal: Endoscopy (2023)

Correction to: Efficacy and cost-effectiveness of a novel dual grasping forceps-assisted over-the-scope clip inverted closure after gastric endoscopic full-thickness resectionEndoscopy 2023; 55(S 01): E870-E871DOI: 10.1055/a-2108-1037
Clinical characteristics and predictors of human mpox outcome during the 2022 outbreak in Nigeria: a cohort study
Authors: Dimie Ogoina, Mahmood Muazu Dalhat, Ballah Akawu Denue, Mildred Okowa, Nneka Marian Chika-Igwenyi, Hakeem Abiola Yusuff, Umenzekwe Chukwudi Christian, Olukemi Adekanmbi, Anastacia Okwudili Ojimba, John Tunde Aremu, Kambai Lalus Habila, Sebastine Oseghae Oiwoh, Ekaete Alice Tobin, Simon Mafuka Johnson, Abimbola Olaitan, Chizaram Onyeaghala, Simji Samuel Gomerep, Datonye Alasia, Asukwo E Onukak, Juliet Mmerem, Uche Unigwe, Olanrewaju Falodun, Vivian Kwaghe, Sati Klein Awang, Mogaji Sunday, Chiedozie James Maduka, Aliyu Mamman Na'uzo, Sampson Omagbemi Owhin, Abdullahi Asara Mohammed, Mukhtar Abdulmajid Adeiza
Journal: The Lancet Infectious Diseases (2023)
ANCA-associated large and small vessel vasculitis with aorto-pulmonary-renal syndrome
Authors: Tajamul H Mir, Parvaiz A Zargar, Bushra Jabeen, Muzamil Latief, Alok Sharma, Nisar A Wani, Syed Mubashir Nissar, Aabid Hussain, Abid Kuchay, Abdul Rasheed Ahangar, Murtaza Rashid Pala, M Omar Parvaiz
Journal: The Lancet Rheumatology (2023)